HER2 in solid tumors: More than 10 years under the microscope; Where are we now?

Future Oncology

Volumn 10, Issue 8, 2014, Pages 1469-1486

  Martin, Vittoria ^a   Cappuzzo, Federico ^b   Mazzucchelli, Luca ^a   Frattini, Milo ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

breast cancer; colorectal cancer; FISH; gastric cancer; HER2; immunohistochemistry; solid tumors; targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; LAPATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; MONOCLONAL ANTIBODY; TUMOR MARKER;

BLADDER CANCER; BLADDER TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL PRACTICE; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOWER ESOPHAGUS SPHINCTER; LUNG CANCER; LUNG TUMOR; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SALIVARY GLAND TUMOR; SOLID TUMOR; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84905244881     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.19     Document Type: Review

References (147)

1. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4, 362-366 (1989).
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997).
3. Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16, 5276-5287 (1996).
4. Lenferink AE, Pinkas-Kramarski R, van de Poll ML et al. Differential endocytic routing of homo-and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17, 3385-3397 (1998).
5. Gajria D, Chandarlapaty S. HER2-amplifed breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 11, 263-275 (2011).
6. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13, 224 (2011).
7. Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann. Oncol. 23, 3007-3016 (2012).
8. Herter-Sprie GS, Greulich H, Wong KK. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front. Oncol. 3, 86 (2013).
9. Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell. Proteomics 3, 379-398 (2004).
10. COSMIC: Catalogue of Somatic Mutations in Cancer. ERBB2. http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=ERBB2
11. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
12. Tapia C, Glatz K, Novotny H et al. Close association between HER-2 amplifcation and overexpression in human tumors of non-breast origin. Mod. Pathol. 20, 192-198 (2007).
13. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann. Oncol. 12(Suppl. 1), S81-S87 (2001).
14. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplifcation of the HER-2/neu oncogene. Science. 235, 177-182 (1987).
15. Tanner M, Hollmén M, Junttila TT et al. Amplifcation of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplifcation, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005).
16. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 376, 687-697 (2010).
17. Ooi A, Takehana T, Li X et al. Protein overexpression and gene amplifcation of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fuorescent in situ hybridization study. Mod. Pathol. 17, 895-904 (2004).
18. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplifcation in colorectal cancer. J. Clin. Pathol 60, 768-772 (2007).
19. Herreros-Villanueva M, Rodrigo M, Claver M et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol. Biol. Rep. 38, 1315-1320 (2011).
20. Cornolti G, Ungari M, Morassi ML et al. Amplifcation and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch. Otolaryngol. Head Neck Surg. 133, 1031-1036 (2007).
21. Lae M, Couturier J, Oudard S et al. Assessing HER2 gene amplifcation as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 21, 815-819 (2010).
22. Tuefferd M, Couturier J, Penault-Llorca F et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2, e1138 (2007).
23. Vermeij J, Teugels E, Bourgain C et al. Genomic activation of the EGFR and HER2-neu genes in a signifcant proportion of invasive epithelial ovarian cancers. BMC Cancer 8, 3 (2008).
24. Pellegrini C, Falleni M, Marchetti A et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fuorescence in situ hybridization, and immunohistochemistry. Clin. Cancer Res. 9, 3645-3652 (2003).
25. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. 22, 1180-1187 (2004).
26. Grob TJ, Kannengiesser I, Tsourlakis MC et al. Heterogeneity of ERBB2 amplifcation in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod. Pathol. 25, 1566-1573 (2012).
27. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic signifcance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440-2447 (2001).
28. Slamon DJ, Leyland-Jones B, Shak S et al Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
29. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007)
30. ClincalTrials.gov. www.clincaltrials.gov
31. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977-984 (2007).
32. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009).
33. Gampenrieder SP, Rinnerthaler G, Greil R. neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J. Oncol. 2013, 732047 (2013).
34. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13, 224 (2011).
35. Chandarlapaty S, Sakr RA, Giri D et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin. Cancer Res. 18, 6784-6791 (2012).
36. Hanker AB, Pfefferle AD, Balko JM et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl Acad. Sci. USA 110, 14372-14377 (2013).
37. Rexer BN, Arteaga CL. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res. 73, 3817-3820 (2013).
38. Harbeck N. American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies. Future Oncol. 9, 1433-1436 (2013).
39. Kim SY, Kim HP, Kim YJ et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplifcation synergistically with cisplatin. Int. J. Oncol. 32, 89-95 (2008).
40. Chung C, Lam MS. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer. Am. J. Health Syst. Pharm. 70, 1579-1587 (2013).
41. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006).
42. Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2-positive breast cancer. Curr. Oncol. Rep. 10, 10-17 (2008).
43. Goss PE, Smith IE, O'Shaughnessy J et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, Phase 3 trial. Lancet Oncol. 14, 88-96 (2013).
44. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2, 127-137 (2002).
45. Smith MB, Reardon J, Olson EM. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer. Drugs Today (Barc.) 48, 713-722 (2012).
46. Langdon SP, Cameron DA. Pertuzumab for the treatment of metastatic breast cancer. Expert Rev. Anticancer Ther. 13, 907-918 (2013).
47. Metzger Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin. Cancer Res. 19, 5552-5556 (2013).
48. Blumenthal GM, Scher NS, Cortazar P et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin. Cancer Res. 19, 4911-4916 (2013).
49. Khasraw M, Bell R. Primary systemic therapy in HER2-amplifed breast cancer: a clinical rev iew. Expert Rev. Anticancer Ther. 12, 1005-1013 (2012).
50. Nielsen DL, Kümler I, Palshof JA et al. Effcacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 22, 1-12 (2013).
51. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 17, 536-542 (2012).
52. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130 (2010).
53. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
54. Ballantyne A, Dhillon S. Trastuzumab emtansine: frst global approval. Drugs 73, 755-765 (2013).
55. Goldenberg MV. Pharmaceutical approval update. PT 38, 246-258 (2013).
56. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698-2704 (2010).
57. Bighin C, Pronzato P, Del Mastro L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol. 9, 955-957 (2013).
58. Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 18, 1473-1479 (2013).
59. Barok M, Tanner M, Köninki K et al. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 306, 171-179 (2011).
60. Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev. Oncol. Hematol. 85, 350-362 (2013).
61. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplifcation of the HER-2/neu oncogene. Science 235, 177-182 (1987).
62. Winstanley J, Cooke T, Murray GD et al. The long term prognostic signifcance of c-erbB-2 in primary breast cancer. Br. J. Cancer 63, 447-450 (1991).
63. Pauletti G, Godolphin W, Press MF et al. Detection and quantitation of HER-2/neu gene amplifcation in human breast cancer archival material using fuorescence in situ hybridization. Oncogene 13, 63-72 (1996).
64. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
65. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J. Clin. Oncol. 31, 3997-4013 (2013).
66. Hanna WM, Rüschoff J, Bilous M et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. (2013) (In Press).
67. Marchiò C, Lambros MB, Gugliotta P et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fuorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 219, 16-24 (2009).
68. Yeh IT, Martin MA, Robetorye RS et al. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 22, 1169-1175 (2009).
69. Troxell ML, Bangs CD, Lawce HJ et al. Evaluation of Her-2/neu status in carcinomas with amplifed chromosome 17 centromere locus. Am. J. Clin. Pathol. 126, 709-716 (2006).
70. Egervari K, Kosa C, Szollosi Z. Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer. Pathol. Res. Pract. 207, 468-471 (2011)
71. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman
72. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117, 48-53 (2011).
73. Zhu X, Lu Y, Lu H et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Hum. Pathol. 42, 1499-1504 (2011).
74. Burrell RA, Juul N, Johnston SR et al. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J. Cell Biochem. 111, 782-790 (2010).
75. Orsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplifcation. J. Clin. Pathol. 66, 1070-1075 (2013).
76. Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61, 818-824 (2008).
77. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fuorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199, 418-423 (2003).
78. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333 (2009).
79. Ohlschlegel C, Zahel K, Kradolfer D et al. HER2 genetic heterogeneity in breast carcinoma. J. Clin. Pathol. 64, 1112-1116 (2011).
80. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fuorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity Am. J. Clin. Pathol. 136, 864-871 (2011).
81. Chang MC, Malowany JI, Mazurkiewicz J et al. 'Genetic heterogeneity' in HER2/neu testing by fuorescence in situ hybridization: a study of 2, 522 cases. Mod. Pathol. 25, 683-688 (2012).
82. Shaf H, Astvatsaturyan K, Chung F, Mirocha J, Schmidt M, Bose S. Clinicopathological signifcance of HER2/neu genetic heterogeneity in HER2/neu non-amplifed invasive breast carcinomas and its concurrent axillary metastasis. J. Clin. Pathol. 66, 649-654 (2013).
83. Starczynski J, Atkey N, Connelly Y et al. HER2 gene amplifcation in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am. J. Clin. Pathol. 137, 595-605 (2012).
84. Vance GH, Barry TS, Bloom KJ et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch. Pathol. Lab. Med. 133, 611-612 (2009).
85. Bartlett JM, Ibrahim M, Jasani B et al. External quality assurance of HER2 fuorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J. Clin. Pathol. 60, 816-819 (2007).
86. Martin V, Camponovo A, Ghisletta M et al. Internal quality assurance program for ERBB2 (HER2) testing improves the selection of breast cancer patients for treatment with trastuzumab. Patholog. Res. Int. 261857 (2012) (2012).
87. Hechtman JF, Polydorides AD. HER2/neu gene amplifcation and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch. Pathol. Lab. Med. 136, 691-697 (2012).
88. Tanner M, Hollmén M, Junttila TT et al. Amplifcation of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplifcation, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16, 273-278 (2005).
89. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19, 1523-1529 (2008).
90. Cruz-Reyes C, Gamboa-Dominguez A. HER2 amplifcation in gastric cancer is a rare event restricted to the intestinal phenotype. Int. J. Surg. Pathol. 21, 240-246 (2013).
91. Park DI, Yun JW, Park JH et al. HER-2/neu amplifcation is an independent prognostic factor in gastric cancer. Dig. Dis. Sci. 51, 1371-1379 (2006).
92. Chen C, Yang JM, Hu TT et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch. Med. Res. 44, 380-389 (2013).
93. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797-805 (2008).
94. Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457, 299-307 (2010).
95. Lee S, de Boer WB, Fermoyle S et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59, 832-840 (2011).
96. Radu OM, Foxwell T, Cieply K et al. HER2 amplifcation in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fuorescence in situ hybridization. Am. J. Clin. Pathol. 137, 583-594 (2012).
97. Ross JS, Mulcahy M. HER2 testing in gastric/gastroesophageal junction adenocarcinomas: unique features of a familiar test. Gastrointest. Cancer Res. 4, 62-66 (2011).
98. Tafe LJ, Janjigian YY, Zaidinski M et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fuorescence in situ hybridization. Arch. Pathol. Lab. Med. 135, 1460-1465 (2011)
99. Herceptin: trastuzumab. www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000278/human-med-000818. jsp&mid=WC0b01ac058001d124
100. FDA approval for trastuzumab. www.cancer.gov/cancertopics/druginfo/fda-trastuzu mab
101. Bartlett JM, Starczynski J, Atkey N et al. HER2 testing in the UK: recommendations for breast and gastric insitu hybridisation methods. J. Clin. Pathol. 64, 649-653 (2011).
102. Kim MA, Lee HJ, Yang HK et al. Heterogeneous amplifcation of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59, 822-831 (2011).
103. Marx AH, Tharun L, Muth J et al. HER-2 amplifcation is highly homogenous in gastric cancer. Hum. Pathol. 40, 769-777 (2009).
104. Cho EY, Park K, Do I et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod. Pathol. 26, 677-684 (2013).
105. Drebber U, Madeja M, Odenthal M et al. p-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. Int. J. Colorectal Dis. 26, 1127-1134 (2011).
106. Kapitanovi S, Radosevi S, Kapitanovi M et al. The expression of p 185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103-1113 (1997).
107. Martin V, Landi L, Molinari F et al. HER2 gene copy number status may infuence clinical effcacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br. J. Cancer 108, 668-675 (2013).
108. Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front. Oncol. 3, 114 (2013).
109. Li Q, Wang D, Li J et al. Clinicopathological and prognostic signifcance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 11, 277 (2011).
110. Lu Y, Jingyan G, Baorong S et al. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark. 11, 219-226 (2012).
111. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifes HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
112. Sorscher SM. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplifed rectal cancer. Cancer Invest. 29, 456-459 (2011).
113. Yonesaka K, Zejnullahu K, Okamoto I et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
114. Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res. 10, 944-946 (2004).
115. Hillig T, Thode J, Breinholt MF et al. Assessing HER2 amplifcation by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fxed paraffn embedded tissue from 40 women with ovarian cancer. APMIS 120, 1000-1007 (2012).
116. Giannoni C, El-Naggar AK, Ordonez NG et al. C-erbB-2/neu oncogene and Ki67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol. Head Neck Surg. 112, 391-398 (1995).
117. Shintani S, Funayama T, Yoshihama Y et al. Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res. 15, 2623-2626 (1995).
118. Khan AJ, Digiovanna MP, Ross DA et al. Adenoid cystic carcinoma: a retrospective clinical review. Int. J. Cancer. 96, 149-158 (2001).
119. Press MF, Pike MC, Hung G et al. Amplifcation and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 54, 5675-5682 (1994).
120. Ching CB, Amin MB, Tubbs RR et al. HER2 gene amplifcation occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod. Pathol. 24, 1111-1119 (2011).
121. Schneider SA, Sukov WR, Frank I et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplifcation identifes patients with poor outcome. Mod. Pathol. (2013) (In press).
122. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fuorescence in situ hybridization associates with increased sensitivity to geftinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838-6845 (2005).
123. Firwana B, Atassi B, Hasan R et al. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature. J. Med. 2, 71-73 (2012).
124. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med. Oncol. 29, 704-706 (2012).
125. Kadowaki S, Yatabe Y, Hirakawa H et al. Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma. Case Rep. Oncol. 6, 450-455 (2013).
126. Haddad RI, Colevas AD, Glisson B et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study. Oral Oncol. 39, 724-727 (2003).
127. Simonetti S, Russo R, Ciancia G et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fsh analysis of c-erbB-2 gene and chromosome 17. Int. J. Surg Pathol. 17, 198-205 (2009).
128. Inoue T, Sato K, Tsuchiya N et al. Numeric aberrations of HER2 and chromosome 17 detected by fuorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma. Urology 64, 617-621 (2004).
129. Skagias L, Politi E, Karameris A et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J. BUON 14, 457-462 (2009).
130. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218-2224 (2007).
131. Peyromaure M, Scotté F, Amsellem-Ouazana D et al. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur. Urol. 48, 771-775 (2005).
132. Salzberg M, Borner M, Bauer JA et al. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur. J. Cancer 42, 2660-2661 (2006).
133. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat. Rev. 32, 180-190 (2006).
134. Hogdall EV, Christensen L, Kjaer SK et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98, 66-73 (2003).
135. Lassus H, Leminen A, Vayrynen A et al. ERBB2 amplifcation is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol. Oncol. 92, 31-39 (2004).
136. Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann. Oncol. 15, 104-112 (2004).
137. Verri E, Guglielmini P, Puntoni M et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic signifcance. Clinical study. Oncology 68, 154-161 (2005).
138. Farley J, Fuchiuji S, Darcy KM et al. Associations between ERBB2 amplifcation and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol. Oncol. 113, 341-347 (2009).
139. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 104, 1241-1245 (2011).
140. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283-290 (2003).
141. Tan D, Deeb G, Wang J et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fuorescent in situ hybridization. Diagn. Mol. Pathol. 12, 201-211 (2003).
142. Gatzemeier U, Groth G, Butts C et al. Randomized Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 15, 19-27 (2004).
143. Zinner RG, Glisson BS, Fossella FV et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a Phase II trial and fndings regarding optimal identifcation of patients with Her2-overexpressing disease. Lung Cancer 44, 99-110 (2004).
144. Clamon G, Herndon J, Kern J et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a Phase II trial of cancer and leukemia group B. Cancer 103, 1670-1675 (2005).
145. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31, 1997-2003 (2013).
146. Stephens P, Hunter C, Bignell G et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
147. Herter-Sprie GS, Greulich H, Wong KK. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front. Oncol. 3, 86 (2013).